From “No Cure” to Near Remission: A Stage 4 Ovarian Cancer Story
When Babette was diagnosed with stage 4 ovarian cancer, she was told the same thing again and again:
there was no cure, only the hope of buying more time.
For more than four years, her life revolved around chemotherapy schedules, scan results, and waiting. Treatment kept the disease from advancing, but never fully eliminated it.
“I knew there had to be more than that,” Babette said.
When Standard Care Reaches Its Limits
She was deeply grateful for her medical team. Her doctors were skilled and honest. But they were also clear about the limits of what conventional treatment could offer. At one pivotal moment, her surgeon told her plainly:
“We have no cure. The best we can offer is more time.”
That conversation changed how Babette thought about her next steps.
She wasn’t looking to abandon medicine or chase a miracle cure. She wanted for a science-driven approach that addressed what she felt was missing: meaningful engagement of the immune system.
Moving Beyond Standard Protocols
In 2022, while traveling in Italy, Babette opened an email from Heal Navigator about alternative cancer treatment options. One phrase immediately stood out: dendritic cell immunotherapy.
“I had researched it years earlier and never qualified,” she recalled. “This time, something told me to take another look.”
Heal Navigator reviewed her medical records, coordinated additional testing, and facilitated direct conversations between Babette’s U.S.-based oncologist and the team at Immunocine Cancer Center in Cancun.
After careful clinical review and collaboration on both sides, Babette was approved.
“That phone call felt like a door opening,” she said. “After years of being told what couldn’t be done, someone was finally saying, ‘Let’s look closer.’”
A Life-Changing Choice: Immunocine Cancer Center, Mexico
Immunocine’s approach focused on personalized dendritic cell immunotherapy, using a patient’s own tumor tissue and immune cells. Just as important for Babette, the clinic worked transparently with her U.S. oncology team and spoke candidly about expectations and limitations.
“I wanted something that worked with conventional care, not against it,” she explained.
Inside the Treatment Experience
Babette began treatment in November 2022. Here’s a brief look at what her Immunocine Protocol involved.
Dendritic Cell Treatment (IDCT): Using her own white blood cells and a tumor biopsy to “train” her immune system.
Interferon Injections: To help send the newly trained white blood cells directly into the tumors.
Checkpoint Inhibitors (Keytruda): A strategic “boost” (only 3 infusions) to prevent immune exhaustion.
The process was meticulous and closely monitored, from tumor biopsy and immune cell collection to lab-guided adjustments throughout care.
“The level of care surprised me,” she noted. “Every step was explained. I wasn’t rushed. I wasn’t dismissed.”
Each treatment triggered a strong but expected immune response. While physically demanding, Babette understood exactly why it was happening.
“My immune system was finally doing what it was meant to do,” she said.
The Results
When Babette began treatment, she had three tumors in her pelvic area.
By May 2023:
- Two tumors had completely resolved
- The third had shrunk to just 1.5 cm of active tissue
Later, in coordination with her U.S. oncologist, Babette added a limited number of Keytruda infusions to support the immune response.
“After four and a half years,” she said, “I could finally see the end of this chapter.”
Life Beyond Survival
Today, Babette is moving forward without cancer defining every decision. She describes this phase as both humbling and grounding.
“For so long, survival was the focus,” she said. “Now I’m learning how to live again.”
Babette is now a holistic health practitioner who uses her experience to guide others. “I feel like I won the lottery,” she says. “And now I want to share the wealth.”
